{"id":34117,"date":"2025-05-26T14:19:26","date_gmt":"2025-05-26T06:19:26","guid":{"rendered":"https:\/\/flcube.com\/?p=34117"},"modified":"2025-05-26T14:19:26","modified_gmt":"2025-05-26T06:19:26","slug":"bayers-eylea-8-mg-close-to-eu-approval-for-longer-treatment-intervals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34117","title":{"rendered":"Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals"},"content":{"rendered":"\n

German pharmaceutical giant Bayer (ETR: BAYN<\/a>) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.<\/p>\n\n\n\n

Current Indications<\/strong>
Aflibercept, a VEGFR-Fc fusion protein co-developed by Bayer and Regeneron, was first approved in the U.S. in November 2011 under the brand name Eylea. Current indications include nAMD, retinal vein occlusion (RVO), diabetic retinopathy, and other ocular disorders.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for…<\/p>\n","protected":false},"author":1,"featured_media":34118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,44],"class_list":["post-34117","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-ophthalmology"],"yoast_head":"\nBayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34117\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34117\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T06:19:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals\",\"datePublished\":\"2025-05-26T06:19:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117\"},\"wordCount\":146,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2608.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34117#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34117\",\"name\":\"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2608.webp\",\"datePublished\":\"2025-05-26T06:19:26+00:00\",\"description\":\"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\\\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34117\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2608.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2608.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34117#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34117","og_locale":"en_US","og_type":"article","og_title":"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals","og_description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.","og_url":"https:\/\/flcube.com\/?p=34117","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-26T06:19:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34117#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34117"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals","datePublished":"2025-05-26T06:19:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34117"},"wordCount":146,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34117#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","keywords":["Bayer","ETR: BAYN","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34117#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34117","url":"https:\/\/flcube.com\/?p=34117","name":"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34117#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34117#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","datePublished":"2025-05-26T06:19:26+00:00","description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the label extension of Eylea 8 mg (aflibercept 8 mg, 114.3 mg\/mL injection). This extension would allow treatment intervals of up to 6 months for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved by the European Commission in the coming weeks, Eylea 8 mg will become the only anti-VEGF therapy in the EU with a 6-month dosing interval for both conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34117#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34117"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34117#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","width":1080,"height":608,"caption":"Bayer's Eylea 8 mg Close to EU Approval for Longer Treatment Intervals"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34117#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2608.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34117"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34117\/revisions"}],"predecessor-version":[{"id":34119,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34117\/revisions\/34119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34118"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}